Abstract 19159: Apob48 as a Marker of Atherosclerosis in Patients with Familial Lipid Disorders, Type 2 Diabetes Mellitus and Coronary Artery Disease
Objective: Postprandial accumulation of atherogenic remnants has been described in patients with type 2 diabetes mellitus (T2DM), familial combined hyperlipidemia (FCH), familial hypercholesterolemia (FH) and coronary artery disease (CAD). Scarce data are available on plasma apoB48 levels in relation to these conditions and atherosclerosis.
Methods: Treated patients with FCH (18), FH (20), T2DM (26), CAD (64), T2DM with CAD (28) and 41 healthy controls were included. All subjects underwent fasting blood sample analysis and intima media thickness (IMT) measurements to investigate subclinical atherosclerosis.
Results: Patients with CAD and both T2DM and CAD were significantly older than the other groups. BMI and waist circumference were higher in T2DM and CAD patients with T2DM when compared to other groups. LDL-C and total apoB were lowest in patients with T2DM and CAD due to more frequent use of lipid lowering medication. Fasting plasma apoB48 was significantly elevated in patients with FCH (11.4±6.0 mg/L) and in T2DM patients with CAD (9.7±6.0 mg/L) compared to the other groups (ANOVA, P<0.001). Subjects with T2DM without CAD, FH and healthy subjects did not differ in fasting apoB48 concentrations. IMT was highest in subjects with CAD (0.72±0.13 mm) and in T2DM patients with CAD (0.77±0.13 mm). In the total group, the best association for apoB48 was found with fasting TG (Pearson's r=0,70; P<0.001). In the subjects not using statins (n=72) the best correlation was found with IMT (0.53; P<0.001), whereas total apoB was not associated to IMT (r=0.18, P=0.15).
Conclusions: ApoB48 concentrations are highest in patients with FCH and in atherosclerotic subjects with T2DM. In patients not using statins, the surrogate atherosclerosis marker IMT correlates best with apoB48 suggesting that fasting apoB48 may help to detect subjects at risk.
- © 2010 by American Heart Association, Inc.